2002
DOI: 10.1097/00007890-200203270-00006
|View full text |Cite
|
Sign up to set email alerts
|

Blockade of CD40-CD154 at the time of donor-specific blood transfusion does not lead to prolonged kidney allograft survival in nonhuman primates1

Abstract: DST under the cover of relatively high levels of anti-CD154 failed to result in prolonged graft survival or prevent the formation of antidonor antibodies, when cyclosporine was given after transplantation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
9
1

Year Published

2002
2002
2007
2007

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 16 publications
(12 citation statements)
references
References 26 publications
2
9
1
Order By: Relevance
“…Intrathymic injection is tolerogenic in rodents, and the thymus is readily accessible at cardiac transplantation (50,55). Unfortunately, fresh unseparated BMC, infused either intravenously or intrathymically, consistently accelerated sensitization to donor antigens, as also seen with a similar intravenous regimen in rhesus monkeys (56). Re- duced immunogenicity of the innoculum or enhanced integrity of costimulatory blockade may circumvent this problem.…”
Section: Discussionmentioning
confidence: 95%
“…Intrathymic injection is tolerogenic in rodents, and the thymus is readily accessible at cardiac transplantation (50,55). Unfortunately, fresh unseparated BMC, infused either intravenously or intrathymically, consistently accelerated sensitization to donor antigens, as also seen with a similar intravenous regimen in rhesus monkeys (56). Re- duced immunogenicity of the innoculum or enhanced integrity of costimulatory blockade may circumvent this problem.…”
Section: Discussionmentioning
confidence: 95%
“…The biopsies and the necropsy materials were scored for rejection according to the Banff '97 criteria (16). Results of these studies have been reported previously (9)(10)(11)15,(17)(18)(19)(20). Biopsies were divided into groups according to the presence or absence of rejection and subsequently according to the type of rejection.…”
Section: Animalsmentioning
confidence: 99%
“…), 2 to 10 mg/kg) once daily either up to day 35 posttransplantation or for 4-6 months (15,(18)(19)(20), or in one case, for 12 months (19). Some animals received prior to tissue sampling Rapamycine (Wyeth), orally once daily up to day 20 posttransplantation (18) and/or aCD3 toxin, intravenous (i.v.)…”
Section: Immunosuppressive Treatmentmentioning
confidence: 99%
“…In brief, cyclosporine A (CsA) (Sandimmune; Novartis, Basel, Switzerland) was given intramuscularly (2-10 mg/kg) once daily either up to day 35 days posttransplantation or for 4 to 6 months (17,19,20). Rapamycin (Rapamune; Wyeth Collegeville, PA) was given orally once daily up to day 20 posttransplantation (21).…”
Section: Immunosuppressive Treatmentmentioning
confidence: 99%